NRG GY016

Primary Category:

Treatment Protocols

Disease Category:

Gynecologic, Ovarian

Status:

Closed

A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary

NCT#03602586

GY016 is permanently closed to accrual and will not advance to second stage accrual, effective February 1, 2021.